Braidwell LP Takes Position in GH Research PLC $GHRS

Braidwell LP acquired a new stake in shares of GH Research PLC (NASDAQ:GHRS) during the second quarter, according to its most recent filing with the SEC. The fund acquired 207,240 shares of the company’s stock, valued at approximately $5,571,000.

Other institutional investors have also added to or reduced their stakes in the company. Lynx1 Capital Management LP boosted its stake in GH Research by 27.5% in the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after purchasing an additional 1,854,238 shares during the period. Avoro Capital Advisors LLC bought a new stake in shares of GH Research during the fourth quarter valued at about $22,860,000. Millennium Management LLC increased its position in shares of GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after buying an additional 659,957 shares during the period. Troluce Capital Advisors LLC lifted its holdings in shares of GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after buying an additional 617,260 shares in the last quarter. Finally, RTW Investments LP lifted its holdings in shares of GH Research by 6.5% in the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after buying an additional 364,251 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Trading Up 2.6%

Shares of GHRS opened at $28.07 on Thursday. GH Research PLC has a 12-month low of $11.83 and a 12-month high of $31.44. The company has a market cap of $1.93 billion, a PE ratio of -28.07 and a beta of 1.27. The stock has a 50-day moving average price of $28.10 and a 200-day moving average price of $21.84.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. As a group, analysts predict that GH Research PLC will post -1.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GHRS. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective for the company. Needham & Company LLC increased their target price on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Zacks Research upgraded shares of GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of GH Research in a report on Monday, August 10th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, GH Research currently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.